Drugs / ARV-393
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06393738 | Sep 2024 → Mar 2028 expected | B-cell non-Hodgkin lymphoma, angioimmunoblastic T-cell lymphoma | Arvinas Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARV-393 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06393738 ↗ |
| Action | Inhibit | “ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas” NCT06393738 ↗ |
| Route | Oral | “The investigational drug will be given as an oral tablet” NCT06393738 ↗ |